You are here > News and publications

News and publications

Promethera Biosciences successfully enrolls twenty patients in its multicentric Phase I/II trial



Promethera Biosciences has conducted the trial in Belgium, France, United Kingdom, Italy and Israel, successfully treating twenty patients affected by very rare liver-based metabolic diseases


Mont-Saint-Guibert (Belgium) - November 12, 2013 – Promethera Biosciences, a Belgian biotechnology company developing Promethera® HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announces today the completion of patient enrolment for its first clinical trial. 


Promethera Biosciences is conducting a first-in-man trial with HepaStem in paediatric patients suffering from orphan diseases. This trial is a prospective, open label, multicenter Phase I/II clinical study involving Urea Cycle Disorders (UCD) and Crigler-Najjar (CN) syndrome paediatric patients.



Télécharger ce fichier (FR)


Download this file (EN)







PROMETHERA Biosciences S.A./N.V.
Watson & Crick Hill
Rue Granbonpré, 11
B-1435 Mont-Saint-Guibert
Tél.: +32 (0)10 39 43 00
Fax: +32 (0)10 39 43 01

News and Public release

CEO John Tchelingerian to Discuss Strategic Collobarations and Partnering Strategies in Cell Therapy at ARM’s Advanced Therapies Summit
Collaboration to Drive Development and Commercialization of Promethera’s Cell-based Liver-Focused Therapeutics Portfolio in Korea